Compared to Estimates, Myriad (MYGN) Q2 Earnings: A Look at Key Metrics

Myriad Genetics (MYGN) reported Q2 2025 revenue of $213.1 million, a 0.8% year-over-year increase, surpassing consensus estimates by 5.55%, and delivered an EPS of $0.05, a significant 600% surprise against the -$0.01 consensus. While key segments like Hereditary Cancer and Pharmacogenomics exceeded revenue expectations, the stock has underperformed, declining 24.8% over the past month compared to the S&P 500's 1% gain, and carries a Zacks Rank #4 (Sell) indicating potential near-term weakness.

Analysis

Myriad Genetics (MYGN) presented a mixed financial picture for its second quarter of 2025, characterized by significant headline beats that mask underlying operational weaknesses. The company reported revenue of $213.1 million, a 5.55% surprise above the Zacks Consensus Estimate, yet this represented nearly flat year-over-year growth of only 0.8%. Similarly, the EPS of $0.05 was a stark 600% surprise against a consensus loss estimate of -$0.01 but was unchanged from the prior-year period. A deeper look into segment performance reveals a fractured growth story: the Hereditary Cancer and Pharmacogenomics segments beat analyst estimates, with the former growing 5.3% YoY. However, Pharmacogenomics revenue declined 12.1% YoY, and Tumor Profiling revenue fell 3.7% YoY. Furthermore, the Prenatal segment, despite 10.7% YoY growth, missed its revenue estimate. This underlying softness likely explains the severe market disconnect, with the stock returning -24.8% over the past month against the S&P 500's +1% gain. The current Zacks Rank #4 (Sell) suggests this negative sentiment and near-term underperformance could persist despite the positive earnings surprises.

Key Decisions for Investors

• Investors should look beyond the headline EPS beat and scrutinize the stagnant 0.8% year-over-year revenue growth and the significant performance divergence between product segments.
• The 12.1% YoY revenue decline in Pharmacogenomics and the revenue miss in the high-growth Prenatal segment are critical red flags that warrant close monitoring in future quarters.
• Given the stock's recent -24.8% underperformance and its 'Sell' rating from Zacks, a cautious approach is warranted, as the market appears to be pricing in the weak fundamental trends rather than the backward-looking earnings surprise.